MAPS mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.
Summer MAPS Bulletin -
Licenses MDMA Study
MAPS News: August 27, 2010
Dear MAPS members and supporters,
It's easy to live in the present and quickly forget the past. As a
result, the struggles and ultimately the accomplishments of those who worked to
bring about social change are often lost to history.
MAPS Executive Director Rick Doblin, Ph.D., in the truncated
summer edition of the MAPS Bulletin, reflects whether MAPS' efforts to
legitimize psychedelic psychotherapy will one day, and perhaps not far off, be
taken for granted by society.
It's a great question, and a sign of how far we have come in our
path to mainstream psychedelic psychotherapy. Rick caught a glimpse of this
shift already under way when he presented the results of our MDMA-assisted
psychotherapy research to an audience at Kaiser Permanente Hospital in San
Francisco last month. To the group of medical professionals, the challenge to
conduct psychedelic research was almost old news. They, like us, were focused
on the research and potential outcomes.
The days of outlawed psychedelic therapy are fleeting, but only
due to the considerable support of MAPS members over the past 24 years.
If you are not yet a MAPS member, consider becoming one today and
put yourself in the vanguard of important social change. Whether you can give
$25, $250 or $2,500, your gift will move us forward on our road to
mainstreaming psychedelic psychotherapy.
Randolph Hencken, M.A.
Director of Communication and Marketing, MAPS